中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2009年
5期
332-335
,共4页
卢绩%王晓庆%芦志华%侯宇川%陈岐辉%汪岩%姜凤鸣%王春喜
盧績%王曉慶%蘆誌華%侯宇川%陳岐輝%汪巖%薑鳳鳴%王春喜
로적%왕효경%호지화%후우천%진기휘%왕암%강봉명%왕춘희
基因表达%膀胱肿瘤%EZH2基因
基因錶達%膀胱腫瘤%EZH2基因
기인표체%방광종류%EZH2기인
Gene expression%Bladder neoplasms%Enhancer of zeste homolog 2 geneDOI: 10. 3760/cma.j.issn. 1000-6702. 2009.05. 014
目的 探讨EZH2基因在膀胱癌发生及进展中的作用. 方法 应用RT-PCR、蛋白质印迹及免疫细胞化学方法,以前列腺癌细胞株PC-3M作为阳性对照,检测EZH2基因在人膀胱移行细胞癌细胞株T24、EJ、MGH-U1、BIU-87中的表达;采用RT-PCR方法检测45例膀胱移行细胞癌和12例正常膀胱黏膜组织中EZH2基因表达情况.45例膀胱移行细胞癌中表浅性癌(Tis、Ta、T1)31例(68.9%),浸润性癌(T2～T4)14例(31.1%);病理分级G1 13例(28.9%),G2 21例(46.7%),G3 11例(24.4%). 结果 4种膀胱癌细胞株中均有EZH2基因表达.EZH2基因在膀胱移行细胞癌组织中的表达率(82.2%)明显高于正常膀胱黏膜(8.3%,P<0.05),在表浅性膀胱癌中的表达率为74.2%,浸润性膀胱癌中为100.0%,差异无统计学意义(P>0.05).EZH2基因在G1,G2和G3级肿瘤中的表达率分别为61.5%,85.7%和100.0%.随细胞分级程度升高.EZH2表达率有增加趋势,但差异无统计学意义(P>0.05). 结论 EZH2基因可能在膀胱癌的发生及进展中起重要作用,可能成为膀胱癌一个潜在的基因治疗靶点.
目的 探討EZH2基因在膀胱癌髮生及進展中的作用. 方法 應用RT-PCR、蛋白質印跡及免疫細胞化學方法,以前列腺癌細胞株PC-3M作為暘性對照,檢測EZH2基因在人膀胱移行細胞癌細胞株T24、EJ、MGH-U1、BIU-87中的錶達;採用RT-PCR方法檢測45例膀胱移行細胞癌和12例正常膀胱黏膜組織中EZH2基因錶達情況.45例膀胱移行細胞癌中錶淺性癌(Tis、Ta、T1)31例(68.9%),浸潤性癌(T2～T4)14例(31.1%);病理分級G1 13例(28.9%),G2 21例(46.7%),G3 11例(24.4%). 結果 4種膀胱癌細胞株中均有EZH2基因錶達.EZH2基因在膀胱移行細胞癌組織中的錶達率(82.2%)明顯高于正常膀胱黏膜(8.3%,P<0.05),在錶淺性膀胱癌中的錶達率為74.2%,浸潤性膀胱癌中為100.0%,差異無統計學意義(P>0.05).EZH2基因在G1,G2和G3級腫瘤中的錶達率分彆為61.5%,85.7%和100.0%.隨細胞分級程度升高.EZH2錶達率有增加趨勢,但差異無統計學意義(P>0.05). 結論 EZH2基因可能在膀胱癌的髮生及進展中起重要作用,可能成為膀胱癌一箇潛在的基因治療靶點.
목적 탐토EZH2기인재방광암발생급진전중적작용. 방법 응용RT-PCR、단백질인적급면역세포화학방법,이전렬선암세포주PC-3M작위양성대조,검측EZH2기인재인방광이행세포암세포주T24、EJ、MGH-U1、BIU-87중적표체;채용RT-PCR방법검측45례방광이행세포암화12례정상방광점막조직중EZH2기인표체정황.45례방광이행세포암중표천성암(Tis、Ta、T1)31례(68.9%),침윤성암(T2～T4)14례(31.1%);병리분급G1 13례(28.9%),G2 21례(46.7%),G3 11례(24.4%). 결과 4충방광암세포주중균유EZH2기인표체.EZH2기인재방광이행세포암조직중적표체솔(82.2%)명현고우정상방광점막(8.3%,P<0.05),재표천성방광암중적표체솔위74.2%,침윤성방광암중위100.0%,차이무통계학의의(P>0.05).EZH2기인재G1,G2화G3급종류중적표체솔분별위61.5%,85.7%화100.0%.수세포분급정도승고.EZH2표체솔유증가추세,단차이무통계학의의(P>0.05). 결론 EZH2기인가능재방광암적발생급진전중기중요작용,가능성위방광암일개잠재적기인치료파점.
Objective To study the expression of enhancer of zeste homolog 2 (EZH2) gene in transitional cell carcinoma (TCC) of the bladder celt lines, carcinoma tissues and normal bladder tis-sues and to evaluate the roles of EZH2 in the development and progression of bladder carcinoma. Methods RT-PCR, Western-blot and immunocytochemistry were used to analyze the expression of EZH2 of the bladder cell lines (T24, EJ, MGH-U1, BIU-87). The prostate cancer cell line PC-3M was used as an EZH2-positive cell line. EZH2 gene expressions in 45 cases of bladder carcinoma and 12 cases of normal bladder mueosa were detected by RT-PCR. Of cancer cases, 31 were superficial tumors and 14 were invasive tumors; 13 were G1, 21 were G2 and 11 were G3. Results EZH2 was detected in the 4 TCC cell lines. The EZH2 expression rate of TCC (82.2%) was significantly higher than that of normal bladder tissues (8.3%, P<0.05). The expression rate in superficial tumors was 74.2% and in invasive tumors was 100.0%, but there was no significant difference (P>0.05). The expression rates increased with tumor cell grade increase, but there was no significant difference (P> 0.05). Conclusions EZH2 could play an important role in the development and progression of blad-der carcinoma. It could be used as a potential gene therapy target of bladder cancer.
